Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.22 (
cdc2
)
8,319
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Nitric oxide (NO), a multifaceted signaling molecule, regulates a wide array of cell functions, including proliferation, differentiation, cytostasis, and apoptosis, which depend on the cell type and redox status. This study systematically explores the effects of NO donors on promyelocytic HL-60 cell proliferation and apoptosis. The NO donor
DETA
-NO modulated the HL-60 cell cycle in a biphasic manner.
DETA
-NO in lower concentrations (1-100 microM) had a proliferative effect as investigated by [(3)H]thymidine incorporation, BrdU labeling, and cell cycle analysis, whereas cells treated with higher concentrations (250 microM-1 mM) showed cytostasis, apoptosis, mitochondrial membrane potential loss, caspase-3 activity, and dUTP nick-end labeling. The proliferative effect of
DETA
-NO was NO dependent and redox sensitive, as the effect was abolished by cPTIO and DTT pretreatment, respectively. Expression of various cell cycle regulators such as
Cdk2
, cyclin B, and cyclin E was significantly augmented in cells treated with 10-50 microM
DETA
-NO. The proliferative effect of NO was blocked by roscovitine, a
Cdk2
inhibitor. S-nitrosylation of
Cdk2
and an increase in the
Cdk2
-associated kinase activity was observed for the first time in
DETA
-NO-treated cells. This study demonstrates that the
DETA
-NO-mediated biphasic effect was dependent on
Cdk2
nitrosylation/activation and the loss of mitochondrial potential at low and high concentrations, respectively.
...
PMID:Cdk2 nitrosylation and loss of mitochondrial potential mediate NO-dependent biphasic effect on HL-60 cell cycle. 2007 29